← Back to Screener
Connect Biopharma Holdings Limited Ordinary Shares (CNTB)
Price$2.99
Favorite Metrics
Price vs S&P 500 (26W)57.00%
Price vs S&P 500 (4W)1.90%
Market Capitalization$165.61M
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.91
Price vs S&P 500 (YTD)1.26%
Net Profit Margin (TTM)-175.22%
EPS (TTM)$-0.81
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-0.81
EPS (Annual)$-1.00
ROI (Annual)-16.96%
Cash / Share (Quarterly)$0.79
Revenue Growth QoQ (YoY)-99.80%
ROA (Last FY)-15.43%
EBITD / Share (TTM)$-0.83
Operating Margin (TTM)-205.21%
Cash Flow / Share (Annual)$-0.44
P/B Ratio3.94x
P/B Ratio (Quarterly)3.76x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4.88x
Net Interest Coverage (TTM)-86.06x
ROA (TTM)-65.79%
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)11.46x
Quick Ratio (Quarterly)3.27x
3-Month Avg Trading Volume0.19M
52-Week Price Return350.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.74
P/S Ratio (Annual)2587.61x
Asset Turnover (Annual)0.26x
52-Week High$3.82
EPS Excl Extra (Annual)$-1.00
CapEx CAGR (5Y)-50.96%
26-Week Price Return60.99%
Quick Ratio (Annual)11.20x
13-Week Price Return38.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.74x
Enterprise Value$127.262
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-86379.69%
Cash / Share (Annual)$1.69
3-Month Return Std Dev93.50%
Net Income / Employee (TTM)$-1
ROE (Last FY)-16.96%
EPS Basic Excl Extra (Annual)$-1.00
Receivables Turnover (TTM)0.16x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.81
ROI (TTM)-80.40%
P/S Ratio (TTM)6.35x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.66
Price vs S&P 500 (52W)320.94%
Year-to-Date Return3.90%
5-Day Price Return5.40%
EPS Normalized (Annual)$-1.00
ROA (5Y Avg)-54.44%
Net Profit Margin (Annual)-86687.50%
Month-to-Date Return11.83%
EBITD / Share (Annual)$-1.02
Operating Margin (Annual)-90740.62%
LT Debt / Equity (Annual)0.00x
EPS Basic Excl Extra (TTM)$-0.81
P/TBV (Quarterly)3.76x
P/B Ratio (Annual)0.83x
Pretax Margin (TTM)-173.92%
Book Value / Share (Annual)$1.67
Price vs S&P 500 (13W)37.52%
Beta-0.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-80.40%
52-Week Low$0.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CNTBConnect Biopharma Holdings Limited Ordinary Shares | 6.35x | — | — | — | $2.99 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Connect Biopharma is a clinical-stage biopharmaceutical company developing next-generation immune modulators to treat autoimmune diseases and inflammatory conditions. The company leverages expertise in T cell modulation to build a pipeline of small molecule and antibody candidates targeting key inflammation pathways. Its lead programs include CBP-201, CBP-307, and CBP-174.